Description
Nandrolone Phenylpropionate (NPP, Durabolin) is the short-acting phenylpropionate ester of 19-nortestosterone. The shorter side chain gives a substantially shorter half-life of about 4-5 days compared to the decanoate ester (~6-12 days).
Per study reports this practically means typical research protocols with two weekly injections for stable plasma levels. Compared to Deca, NPP allows faster cycle adjustments and shorter taper phases - if side effects occur, mid-protocol redirection can happen faster.
Pharmacology is identical to Deca: low androgenic activity, high anabolic action, weak aromatization to estradiol, 5α-reduction to weakly-androgenic DHN. Prolactin-mediated effects (libido decrease, “Deca dick” phenomenon) are documented as with Deca.
In historical clinical application Durabolin was earlier used for osteoporosis treatment. Today the substance is mainly relevant in the recreational community.
The shorter half-life has an important advantage: shorter detection in doping tests than Deca (but still long compared to testosterone esters).
You can order Nandrolone Phenylpropionate as an oily injection solution in 10-pack at 100mg/ml.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
NPP shares the full risk profile of all Nandrolon esters - the effects described in the literature are identical to Deca, only the shorter half-life allows faster redirection if side effects occur.
Documented in studies and the application literature:
- Progestagenic and prolactinergic action: NPP acts progestagenically and raises prolactin levels. Libido decrease and erectile dysfunction are documented, described in recreational reports as the “Deca dick” phenomenon.
- Suppression of endogenous production: Nandrolon esters strongly suppress endogenous testosterone production and suppress the DHT pathways. Testicular atrophy and reduced fertility are documented, a separate test base is mandatory.
- Weak aromatization: NPP converts only weakly to estradiol, yet water retention is documented at higher doses.
- Cardiovascular and liver: the literature describes an unfavorable lipid profile, cardiac effects in chronic use and mild hepatotoxicity.
Baseline bloodwork before, during and after a research protocol is strongly advised. This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Nandrolone decanoate: Pharmacological properties and therapeutic use in osteoporosis - Clinical Rheumatology 1995, Geusens: review of pharmacology and clinical use of nandrolone esters, applies class-wide to NPP.
- The effects of anabolic steroids on collagen synthesis in rat skeletal muscle and tendon - Am J Sports Med 1992, Karpakka et al: animal study on collagen synthesis in muscle and tendon under anabolic steroids.
- Nandrolone decanoate relieves joint pain in hypogonadal men: a novel prospective pilot study and review of the literature - Transl Androl Urol 2020, Tatem et al: prospective pilot study on nandrolone and joint pain with literature review.
- Effects of Pharmacological Doses of Nandrolone Decanoate and Progressive Resistance Training in Immunodeficient Patients Infected with Human Immunodeficiency Virus - JCEM 1999, Sattler et al: clinical study on nandrolone plus resistance training with lean-mass gains.
- Impact of Nandrolone Decanoate on Gene Expression in Endocrine Systems Related to the Adverse Effects of Anabolic Androgenic Steroids - Basic Clin Pharmacol Toxicol 2009, Alsiö et al: gene-expression study on HPTA suppression and steroid metabolism under nandrolone.
